Chronic Kidney Disease News

The National Kidney Foundation launched a new interactive portal that lets patients with chronic kidney disease learn more about their condition, according to a press release.

The FDA granted full approval to Filspari, a daily oral, non-immunosuppressive medication, to slow kidney function decline in adults with primary IgA nephropathy, according to an industry press release.

During a 20-year period, patients with end-stage kidney disease treated with hemodialysis saw a reduction in mortality worldwide, study results show. The biggest gain in survival was among patients the United States.

Canagliflozin may reduce albuminuria and patient-specific eGFR decline in patients with type 2 diabetes and microalbuminuria, researchers found in a parallel, open-labeled trial.

Automated peritoneal dialysis may be linked to fewer dialysis-related complications and lower initial hospitalization costs compared with hemodialysis for certain patients, according to published data.

Allopurinol and febuxostat were both associated with lower all-cause mortality when used by adults undergoing hemodialysis in Japan; allopurinol also lowered risk of death from CVD events, according to study data.

Adults with chronic kidney disease managed with hemodiafiltration reported less drop in health-related of quality of life, particularly in cognitive decline, compared with those using hemodialysis, according to data from the CONVINCE trial.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Women on in-center hemodialysis generally may experience more headaches and other symptoms than men, according to results of a published cluster study.

Adults with early kidney disease who live in unemployed or lower-skilled households may have higher mortality rates compared with those in professional households, according to published data.